Recent Updates
Recently added Catalysts
SRRK Positive Sentiment Score: 70/100

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Wednesday, July 29, 2026 1 min read
Key Takeaway: Scholar Rock, a biopharmaceutical company focused on spinal muscular atrophy and other neuromuscular diseases, will present at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for August 12, 2026, at 1:30 p.m. ET in Boston, MA. This presentation underscores the company's commitment to advancing its research and development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scholar Rock is dedicated to improving lives affected by SMA.
  • The company is recognized for its innovative platform in myostatin biology.
  • Participation in a prominent conference highlights the company's visibility.

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET. A live webcast of the ev

Frequently Asked Questions

When will Scholar Rock present at the conference?

Scholar Rock will present on August 12, 2026, at 1:30 p.m. ET.

Where is the Canaccord Genuity conference held?

The conference will take place in Boston, MA.

What is Scholar Rock's focus area?

Scholar Rock focuses on spinal muscular atrophy and other neuromuscular diseases.

What is the significance of the conference for Scholar Rock?

The conference highlights Scholar Rock's commitment to advancing its research.

Tags: SRRK Viatris Investor Conferences Healthcare Scholar Rock SMA myostatin biology Canaccord Genuity biopharmaceutical
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$480M liquidity · $27M/mo burn
~15 mo
Low dilution risk
Lead asset
ApitegromabPhase 3
Spinal Muscular Atrophy →

Catalyst track record

+68%
best trade around SRRK's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SRRK.

See every catalyst's timing & PoA →